Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials

American Journal of Gastroenterology

Volumn 94, Issue 3, 1999, Pages 581-595

  Cammà, Calogero ^a   Giunta, Marco ^b   Pinzello, Giovanbattista ^b   Morabito, Alberto ^b   Verderio, Paolo ^b   Pagliaro, Luigi ^b  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RATE; LONG TERM CARE; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ALANINE TRANSAMINASE; DRUG ADMINISTRATION SCHEDULE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RANDOMIZED CONTROLLED TRIALS; RNA, VIRAL;

EID: 0033018806     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00800-4     Document Type: Article

References (143)

1. De Bac C, Stroffolini T, Gaeta GB, et al. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study. Hepatology. 1994;20:1225-30.
2. Herson J. The use of surrogate endpoints in clinical trials (an introduction to series of four papers). Stat Med 1989;8: 403-4.
3. Tine F, Magrin S, Craxì A, et al. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-9.
4. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996;24: 778-89.
5. Cammà C, Giunta M, Linea C, et al. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
6. Poynard T, Bedossa P, Opolon P, for the Obsvirc, Metavir, Clinivir and Dosvirc groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
7. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam consultation on meta-analysis. J Clin Epidemiol 1995;48:167-71.
8. Chayama K, Arasa Y, Koida I, et al. Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J Gastroenterol Hepatol 1994;9:128-33.
9. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992;15:37-41.
10. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992;15:1013-6.
11. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology 1995;21:639-44.
12. Kakumu S, Yoshika K, Tanaka K, et al. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993;41:65-70.
13. Kleter GEM, Brouwer JT, Heijtink RA, et al. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrobiol Agents Chemother 1993;37:595-7.
14. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993 12;341:1501-4.
15. Watanabe S, Kobayashi Y, Konishi M, et al. Appropriate interferon-alpha therapy for chronic hepatitis C: An assessment by quantitative changes in serum hepatitis C virus-RNA. Intern Med 1993;32:523-9.
16. Castillo I, Bartolome J, Navas S, et al. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994;19: 342-6.
17. Reichard O, Foberg U, Frydén, A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a2b for 60 weeks. Hepatology 1994;19:280-5.
18. Saleh MG, Tibbs CJ, Koskinas J, et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994;20:1399-404.
19. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
20. Pol S, Jaffredo F, Nalpas B, et al. Pragmatic monitoring of interferon-a therapy in chronic hepatitis related to hepatitis C virus infection. Unpublished.
21. Shindo M, Arai K, Yoshihiro S, et al. Hepatic Hepatitis C virus RNA as a predictor of long-term response to interferon-therapy. Ann Intern Med 1995;122:586-91.
22. Yamada G, Takatani M, Kishi F, et al. Kolberg JA. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarly on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
23. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-a2b. Hepatology 1993;18:1300-5.
24. Picciotto A, Bardellini E, Borzone S, et al. Virological and biochemical responses to interferon-alpha in chronic hepatitis C. Lancet 1994;343:54-5.
25. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-a in chronic hepatitis C. Ann Intern Med 1996; 124:1058-60.
26. Morisco F, Tuccillo C, Sessa G, Can chronic HCV infection terminate in patients with chronic active hepatitis long-term responders to interferon therapy? Gastroenterology 1995; 108:A1126 (abstract).
27. Carreño V, Gerken G, Trèpo C, et al., and a Multicenter Study Group. Four years of follow-up (LTFUP) of patients with chronic hepatitis C (CHC) treated with interferon-α-2a. Hepatology 1995;22:173A (abstract).
28. Karino Y, Toyota J, Higashino K, et al. Analysis of prognosis of patients with type C chronic hepatitis who treated with interferon. Hepatology 1995;22:177A (abstract).
29. Reichard O, Glaumann H, Frydén A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.
30. Takahashi M, Yamada G, Tsugeno H, et al. Long-term biochemical, virological and histological follow-up in patients with chronic hepatitis C treated with interferon. Hepatology 1995;22:174A (abstract).
31. Ajello A, Freni MA, Spadaro A, et al. Six years follow up of patients with chronic hepatitis C treated with IFN. IX Triennal International Symposium - Roma 1996;C108 (abstract).
32. Craxì A, Di Marco V, Almasio P. Hepatic hepatitis C virus RNA in chronic hepatitis C. Ann Intern Med 1996;124:72 (letter).
33. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C. N Engl J Med 1996;334:1479-80 (letter).
34. Davis GL, Balart LA, Schiff ER, et al., and The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
35. Di Bisceglie A, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
36. Jacyna MR, Brooks MG, Loke RHT, et al. A controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J 1989;298:80-2.
37. Schvarcz R, Glaumann H, Weiland O, et al. Interferon alpha-2b treatment of chronic posttransfusion non-A non-B/C hepatitis: long-term outcome and effect of increase interferon doses in non-responders. Scand J Infect Dis 1991;23:413-20.
38. Farrell G, Lin R, Schoeman M, et al. Interferon alfa-2b for chronic active hepatitis C: Interim results of an Australian trial. J Hepatol 1990;11(suppl 1):S157.
39. Gomez-Rubio M, Porres JC, Castillo I, et al. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol 1990;11(suppl 1):S63-7.
40. Kakumu S, Arao M, Yoshioka K, et al. Recombinant human-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 1990;85:655-9.
41. Realdi G, Diodati G, Bonetti P, et al. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol 1990;11(suppl 1):S68-71.
42. Saracco G, Rosina F, Torrani Cerenzia MR, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11(suppl 1):S43-9.
43. Varagona G, Kibbler H, Smith M, et al. A phase II study of interferon alfa-2b treatment of anti-HCV positive and negative chronic NANB hepatitis: Interim analysis. J Hepatol 1990;11(suppl 1):S165.
44. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101: 497-502.
45. Cimino L, Nardone G, Citarella C, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. Ital J Gastroenterol. 1991;23:399-402.
46. Lin R, Grierson J, Schoeman MN, et al. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C. Aust NZ J Med 1991;21:387-92.
47. Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
48. Omata M, Ito Y, Yokosuka O, et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991;36:1217-22.
49. Saez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant α-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 1991; 13:327-31.
50. Terranova R, Luca S. Treatment of chronic hepatitis C with recombinant interferon alpha-2b. J Chemother 1992;4:297-302.
51. Wejstål R, Norkrans G, Lenkei R, et al. Peripheral blood lymphocyte subset in patients with chronic hepatitis C-effect of interferon treatment. Liver 1992;12:161-7.
52. Alberti A, Chemello L, Bonetti P, et al. and TVVH Study Group. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17: (suppl 3):S123-6.
53. Benelux Multicentre Trial Study Group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: Standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; 34(suppl):S119-20.
54. Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-62.
55. Camps J, Castilla A, Ruiz J, et al. Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17:390-6.
56. Caporaso N, Suozzo R, Morisco F, et al. Recombinant human interferon alfa-2a therapy of chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-6.
57. Capra F, Casaril M, Gabrielli GB, et al. α-Interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers. J Hepatol 1993;18:112-8.
58. Castilla A, Camps-Bansell J, Civeira MP, et al. Lymphoblastoid α-interferon for chronic hepatitis C: A randomized controlled study. Am J Gastroenterol 1993;88:233-9.
59. De Bac C, Grimaldi F, Clementi C, et al. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 1993;34(suppl):S135.
60. Douglas DD, Rakela J, Lin HJ, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993;38:601-7.
61. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
62. Iino S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high-dose interferon α-2b: A multicenter study. Dig Dis Sci 1993;38:612-8.
63. Kagawa T, Morizane T, Saito H, et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993; 17:91-6.
64. Kleter GEM, Brouwer JT, Heijtink RA, et al. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993;37:595-7.
65. Metreau JM, and the French Group for the Study of NANB/C Chronic Hepatitis Treatment. Gut 1993;S112-3.
66. Pérez R, Pravia R, Linares A, et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. Gut 1993;34(suppl):S136-8.
67. Reichen J, Solioz M, Bühler H, et al. Low-dose interferon in chronic hepatitis non-A/non-B: Effects on quantitative liver function and structure in a randomized, controlled multicenter trial. Clin Invest 1993;71:888-93.
68. Sieck JO, Ellis ME, Alfurayh O, et al. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: A randomized placebo-controlled double-blind cross-over study. J Hepatol 1993;19:418-23.
69. Attili AF, Natali L, Onori L, et al. Treatment of type C chronic active hepatitis with interferon-α-2a: Treatment duration does not influence biochemical remission but does decrease the relapse rate. J Clin Gastroenterol 1994;19: 214-6.
70. Budillon G, Cimino L, Del Vecchio Blanco C, et al. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols. Ital J Gastroenterol 1994;26:16-20.
71. Diodati G, Bonetti P, Noventa F, et al. Treatment of chronic hepatitis C with recombinant human interferon-α2a: Results of a randomized controlled clinical trial. Hepatology 1994; 19:1-5.
72. Jouët P, Roudot-Thoraval F, Dhumeaux D, et al., and French Group for the Study of Chronic Hepatitis. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106: 686-90.
73. Matsumoto A, Tanaka E, Suzuki T, et al. Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-80.
74. Mazzella G, Salzetta A, Casanova S, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response. Dig Dis Sci 1994;39:866-70.
75. Negro F, Baldi M, Mondardini A, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-85.
76. Saito T, Shinzawa H, Kuboki M, et al. A randomized controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89:681-5.
77. Angelini G, Sgarbi D, Colombari R, et al. Alpha-interferon treatment of chronic hepatitis C: A controlled, multicentre, prospective study. Digestion 1995;56:199-203.
78. Biøro K, Krarup H, Bell H, et al. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Scand J Gastroenterol 1995;30:1119-24.
79. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
80. Craxì A, Di Marco V, Lo Iacono O, et al. Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months. J Hepatol 1996;24:539-46.
81. Hwang SJ, Chan CY, Lu RH, et al. Randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with chronic hepatitis C. J Inter C 1995;15: 611-6.
82. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21: 291-7.
83. Lin R, Roach E, Zimmerman M, et al., for the Australia Hepatitis C Study Group. Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-96.
84. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
85. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effect of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
86. Poynard T, Bedossa P, Chevallier M, et al., and Multicenter Study Group. A comparison of three interferon alfa-2b regimens for the longterm treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
87. Rumi MG, Del Ninno E, Parravicini ML, et al. Long-term titrated recombinant interferon-α2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepatitis 1995;2:73-6.
88. Yokosuka O, Kato N, Hosoda K, et al. Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 1995;37:721-6.
89. Picciotto A, Callea F, Varagona G, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: Biochemical, virological and histological evaluation of two different doses. Liver 1995;15:20-4.
90. Hakozaki Y, Shirahama T, Katou M, A controlled study to determine the optimal dose regimen of interferon-α 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
91. Enriquez J, Torras X, Miralles F, et al. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: Influence on the levels of ALT, viremia and histological activity. J Viral Hepatitis 1995;2: 181-7.
92. Kakumu S, Yoshioka K, Wakita T, et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507-12.
93. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
94. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Result from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-7.
95. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-a and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-9.
96. Yatsuhashi H, Inoue O, Inokuchi K, et al. Short and long-term effects of interferon on serum markers of hepatitis C virus replication. J Gastroenterol Hepatol 1993;8:1-6.
97. Zielinska W, Paszkiewicz J, Korczak A, et al. Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp Warsz 1993;41:253-7.
98. Bonetti P, Diodati G, Scaccabarozzi S, et al. Treatment of cryptogenic chronic liver diseases with recombinant alpha-2a interferon. Preliminary results of a randomized controlled clinical trial. Ann Ital Med Int 1990;5:169-73.
99. Giudici-Cipriani A, Rainisio C, Ponassi I, et al. Therapy of chronic non-A, non-B hepatitis with interferon alfa-2B. A controlled clinical study and long-term follow-up. Minerva Gastroenterol Dietol 1991;37:85-90.
100. Hopf U, Kuther S, Konig V, et al. Current status of treatment for chronic viral hepatitis using recombinant interferon alpha. Dtsch Med Wochenschr 1994;119:961-4.
101. Hopf U, Moller B, Konig V, et al. Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha. Z Gastroenterol 1990;28:453-7.
102. Saito T, Shinzawa H, Takahashi T. Interferon therapy of compensated type C cirrhosis. Nippon Rinsho 1994;52: 1875-9.
103. Weiland O, Schvarcz R, Wejstål R, et al. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990;11:S57-62.
104. Liaw YF Sheen IS Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results. J Hepatol 1990;11(suppl 1):S160.
105. Farrell GC, Lin R, Coverdale S. Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function. Gastroenterol Jpn 1991;26(suppl 3):243-6.
106. Diodati G, Bonetti P, Tagger A, et al. Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV. Arch Virol 1992;(suppl 4):299-303.
107. Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993;34(suppl):S114-8.
108. Lin R, Liddle C, Farrell GC. Alpha-interferon 2b in the treatment of chronic hepatitis C: Interim report of the first multicentre Australian trial. Gastroenterol Jpn 1993;28: 101-3.
109. Picciotto A, Varagona G, Valle F, et al. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients. J Hepatol 1993;17:359-63.
110. Valla D, Babany G, Ouzan D, et al, and Grp Et Multictr interferon dans Hépatites. Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. J Hepatol 1994;21:774-8.
111. De AlavaE, Camps J, Pardo-Mindán J, Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver 1993;13:73-9.
112. Makris M, Preston FE, Triger DR, et al. A randomized controlled trial of recombinant interferon-a in chronic hepatitis C in hemophiliacs. Blood 1991;78:1672-7.
113. Gallorini A, Plebani M, Pontisso P, et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon. Liver 1994;14:257-64.
114. Chayama K, Arasa Y, Koida I, et al. Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J Gastroenterol Hepatol 1994;9:128-33.
115. Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-4.
116. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994;16:334-43.
117. Tassopoulos NC, Karvountzis G, Touloumi G, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: A randomized controlled trial. Am J Gastroenterol 1996;91:1734-8.
118. Sanchez-Tapias JM, Forns X, Ampurdanes S, et al. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Gut 1996;38:603-9.
119. Toyoda H, Nakano S, Kumada T, et al. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:743-7.
120. Perez R, Pravia R, Artimez ML, et al. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepatitis 1995;2:103-6.
121. Villa E, Trande P, Grottola A, et al. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci 1996;41:1241-7.
122. Ideo G, Bellobuono A, Mondazzi L, et al. Alpha interferon treatment in chronic hepatitis C. Clin Exp Rheumatol 1995; 13:8167-73.
123. Fernandez I, Castellano G, Canga F, et al. A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C. Gastroenterol Hepatol 1995;18:66-72.
124. Passariello N, Sepe J, Peluso A, et al. Treatment of chronic hepatitis C with lymphoblastic interferon. Long-term follow-up. Presse Med 1995;24:1201-6.
125. Shiffman ML, Hofmann CM, Luketic VA, et al. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24:21-6.
126. Yuki N, Hayashi N, Kasahara A, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995;22:457-63.
127. Friedlander L, van Thiel DH, Faruki H, et al. New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease. Dig Dis Sci 1996;41:1678-81.
128. Tanno H, Fernandez JL, Rendo P, et al. Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C. J Viral Hepat 1995;2:97-102.
129. Rumi M, Del Ninno E, Parravicini ML, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24:1366-70.
130. Lindsay KL, Davis GL, Schiff ER, et al., and the Hepatitis Interventional Therapy Group. Response to higher doses of interferon alfa-ab in patients with chronic hepatitis C: Randomized multicenter trial. Hepatology 1996;24:1034-40.
131. Di Marco V, Lo Iacono O, Cammà C, et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997;51:17-24.
132. Eddy MD, Hasselblad V, Shachter R. Meta-analysis by the confidence profile method. The statistical synthesis of evidence. San Diego: Academic Press, 1992.
133. Eddy MD, Hasselblad V. Fast*Pro. Software for meta-analysis by the confidence profile method. San Diego: Academic Press, 1992.
134. Eddy MD, Hasselblad V, Shachter R. An introduction to a Bayesian method for meta-analysis: The confidence profile method. Med Decis Making 1990;10:15-23.
135. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
136. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
137. Collin R, Scrimgeour A, Yusuf D, et al. Reduction in fatal pulmonary embolism and venous thrombosis by peri-operative administration of subcutaneous heparin: Overview of results of randomized trials in general orthopedic and urologic surgery. N Engl J Med 1988;5:1162-73.
138. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995;48:45-57.
139. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
140. SAS Institute Inc. SAS guide for personal computers. Version 6.03. Cary, NC: SAS Institute, 1988.
141. Pagliaro L, Craxì A, Cammà C, et al. Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-8.
142. Niederau C, Heintges T, Häussinger D. Treatment of chronic hepatitis C with α-interferon: An analysis of the literature. Hepato-Gastroenterology 1996;43:1544-56.
143. Janssen HLA, Brouwer JT, Nevens F, et al. Fatal hepatic decompensation associated with interferon alfa. Br Med J 1993;306:107-8.